Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Analyst ; 146(20): 6156-6169, 2021 Oct 11.
Article in English | MEDLINE | ID: mdl-34515271

ABSTRACT

The identification of the most competent embryos for transfer to the uterus constitutes the main challenge of in vitro fertilization (IVF). We established a metabolomic-based approach by applying Fourier transform infrared (FTIR) spectroscopy on 130 samples of 3-day embryo culture supernatants from 26 embryos that implanted and 104 embryos that failed. On examining the internal structure of the data by unsupervised multivariate analysis, we found that the supernatant spectra of nonimplanted embryos constituted a highly heterogeneous group. Whereas ∼40% of these supernatants were spectroscopically indistinguishable from those of successfully implanted embryos, ∼60% exhibited diverse, heterogeneous metabolic fingerprints. This observation proved to be the direct result of pregnancy's multifactorial nature, involving both intrinsic embryonic traits and external characteristics. Our data analysis strategy thus involved one-class modelling techniques employing soft independent modelling of class analogy that identified deviant fingerprints as unsuitable for implantation. From these findings, we could develop a noninvasive Fourier-transform-infrared-spectroscopy-based approach that represents a shift in the fundamental paradigm for data modelling applied in assisted-fertilization technologies.


Subject(s)
Fertilization in Vitro , Metabolomics , Culture Media , Female , Humans , Pregnancy , Spectroscopy, Fourier Transform Infrared
2.
Front Endocrinol (Lausanne) ; 12: 675670, 2021.
Article in English | MEDLINE | ID: mdl-34040586

ABSTRACT

Background: A Delphi consensus was conducted to evaluate global expert opinions on key aspects of assisted reproductive technology (ART) treatment. Methods: Ten experts plus the Scientific Coordinator discussed and amended statements plus supporting references proposed by the Scientific Coordinator. The statements were distributed via an online survey to 35 experts, who voted on their level of agreement or disagreement with each statement. Consensus was reached if the proportion of participants agreeing or disagreeing with a statement was >66%. Results: Eighteen statements were developed. All statements reached consensus and the most relevant are summarised here. (1) Follicular development and stimulation with gonadotropins (n = 9 statements): Recombinant human follicle stimulating hormone (r-hFSH) alone is sufficient for follicular development in normogonadotropic patients aged <35 years. Oocyte number and live birth rate are strongly correlated; there is a positive linear correlation with cumulative live birth rate. Different r-hFSH preparations have identical polypeptide chains but different glycosylation patterns, affecting the biospecific activity of r-hFSH. r-hFSH plus recombinant human LH (r-hFSH:r-hLH) demonstrates improved pregnancy rates and cost efficacy versus human menopausal gonadotropin (hMG) in patients with severe FSH and LH deficiency. (2) Pituitary suppression (n = 2 statements): Gonadotropin releasing hormone (GnRH) antagonists are associated with lower rates of any grade ovarian hyperstimulation syndrome (OHSS) and cycle cancellation versus GnRH agonists. (3) Final oocyte maturation triggering (n=4 statements): Human chorionic gonadotropin (hCG) represents the gold standard in fresh cycles. The efficacy of hCG triggering for frozen transfers in modified natural cycles is controversial compared with LH peak monitoring. Current evidence supports significantly higher pregnancy rates with hCG + GnRH agonist versus hCG alone, but further evidence is needed. GnRH agonist trigger, in GnRH antagonist protocol, is recommended for final oocyte maturation in women at risk of OHSS. (4) Luteal-phase support (n = 3 statements): Vaginal progesterone therapy represents the gold standard for luteal-phase support. Conclusions: This Delphi consensus provides a real-world clinical perspective on the specific approaches during the key steps of ART treatment from a diverse group of international experts. Additional guidance from clinicians on ART strategies could complement guidelines and policies, and may help to further improve treatment outcomes.


Subject(s)
Fertilization in Vitro/standards , Luteal Phase/physiology , Oocytes/growth & development , Oogenesis , Ovulation Induction/standards , Pituitary Gland/drug effects , Reproductive Techniques, Assisted/standards , Chorionic Gonadotropin/administration & dosage , Consensus , Delphi Technique , Female , Follicle Stimulating Hormone, Human/metabolism , Gonadotropin-Releasing Hormone/agonists , Humans , Practice Guidelines as Topic , Pregnancy , Progesterone/metabolism
6.
Reprod Biol Endocrinol ; 18(1): 45, 2020 May 13.
Article in English | MEDLINE | ID: mdl-32404170

ABSTRACT

The prolonged lockdown of health services providing high-complexity fertility treatments -as currently recommended by many reproductive medicine entities- is detrimental for society as a whole, and infertility patients in particular. Globally, approximately 0.3% of all infants born every year are conceived using assisted reproductive technology (ART) treatments. By contrast, the total number of COVID-19 deaths reported so far represents approximately 1.0% of the total deaths expected to occur worldwide over the first three months of the current year. It seems, therefore, that the number of infants expected to be conceived and born -but who will not be so due to the lockdown of infertility services- might be as significant as the total number of deaths attributed to the COVID-19 pandemic. We herein propose remedies that include a prognostic-stratification of more vulnerable infertility cases in order to plan a progressive restart of worldwide fertility treatments. At a time when preventing complications and limiting burdens for national health systems represent relevant issues, our viewpoint might help competent authorities and health care providers to identify patients who should be prioritized for the continuation of fertility care in a safe environment.


Subject(s)
Coronavirus Infections , Fertilization in Vitro , Infertility, Female/therapy , Pandemics , Pneumonia, Viral , Reproductive Health Services/organization & administration , Reproductive Techniques, Assisted , Betacoronavirus , COVID-19 , Coronavirus , Female , Humans , Pregnancy , SARS-CoV-2 , Sperm Injections, Intracytoplasmic
7.
Glob Reprod Health ; 52020 Aug 13.
Article in English | MEDLINE | ID: mdl-34192216

ABSTRACT

The COVID-19 pandemic has posed unique concerns and potential risks to women now pregnant or considering childbearing. Although no professional societies have issued recommendations that women avoid conception at this time, several professional organizations recommended a moratorium on infertility services including both medically assisted reproduction and assisted reproductive technology shortly after the World Health Organization declared COVID-19 infection to be a pandemic. Reasons cited for undertaking these extraordinary measures included prevention of possible complications of assisted reproductive technology and medically assisted reproduction and virus induced complications of pregnancy including potential vertical transmission to the fetus and optimization use of critical health care resources. A survey of reproductive health providers in 97 countries was undertaken to assess their response to the pandemic and recently issued guidance. Although different countries reacted differently with diverse responses and variable resources, the results suggest that the reproductive health community has largely been responsive to public health and individual patient concerns.

10.
Reprod Biomed Online ; 25(6): 600-2, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23063815

ABSTRACT

A 45-year-old woman received embryos from IVF by intracytoplasmic sperm injection (ICSI) with her own oocytes that were cryopreserved (slow freezing in a low-sodium medium) 11 years and 7 and a half months before, when she was 33 years old. From seven metaphase-II oocytes thawed, five survived, four were fertilized after ICSI and two cleaving embryos were transferred on day 3. A diamniotic dichorionic term pregnancy was achieved, ending with the delivery of two healthy girls. As far as is known, this case represents, to date, the longest storage period of cryopreserved human oocytes resulting in a live birth.


Subject(s)
Cryopreservation , Infertility, Female/therapy , Oocytes , Pregnancy, Twin , Sperm Injections, Intracytoplasmic , Ectogenesis , Embryo Transfer , Female , Humans , Live Birth , Middle Aged , Pregnancy , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...